FDA Approves Takeda's Mimrylo For Rare Blood Disorder Polycythemia Vera

FDA approved Takeda’s Mimrylo (rusfertide) as a new treatment for adults with polycythemia vera, a rare blood disorder characterized by excessive red blood cell production. The regulatory milestone meaningfully de-risks the product’s commercialization path and supports a positive outlook for Takeda’s pipeline. Overall sentiment is bullish, though specific financial magnitude (revenue/market size or guidance) was not provided in the excerpt.